Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study—determination of immunogenicity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study—determination of immunogenicity

Published:2024-03-27 Issue:6 Volume:61 Page:531-533
ISSN:0022-2593
Container-title:Journal of Medical Genetics
language:en
Short-container-title:J Med Genet

Author:

Lenders Malte^ORCID,Brand Eva

Publisher

BMJ

Reference10 articles.

1. Safety and efficacy of Pegunigalsidase Alfa in patients with Fabry disease who were previously treated with Agalsidase Alfa: results from BRIDGE, a phase 3 open-label study;Linhart;Orphanet J Rare Dis,2023

2. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

3. Pre-existing anti-drug antibodies in Fabry disease show less affinity for Pegunigalsidase Alfa;Lenders;Mol Ther Methods Clin Dev,2022

4. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease;Lenders;Front Immunol,2023

5. Antibodies against recombinant enzyme in the treatment of Fabry disease: now you see them, now you don't;van der Veen;Mol Ther Methods Clin Dev,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry disease: a rare disorder calling for personalized medicine;International Urology and Nephrology;2024-04-13

2. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study – determination of immunogenicity;Journal of Medical Genetics;2024-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3